Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
03692 HANSOH PHARMA
RTNominal up20.050 +0.450 (+2.296%)
Others

18/02/2021 09:00

Hansoh Pharma (03692) units sign licence agreement

[ET Net News Agency, 18 February 2021] Hansoh Pharmaceutical Group Company Limited
(03692) said its subsidiary Hansoh (Shanghai) Health Technology Co., Ltd. and Jiangsu
Hansoh Pharmaceutical Group Company Ltd. (collectively, the licensees) have entered into
an exclusive licence and collaboration agreement with SCYNEXIS, Inc. (NASDAQ: SCYX).
The licensees will obtain an exclusive licence from SCYNEXIS to research, develop and
commercialize ibrexafungerp in the People's Republic of China. In consideration for the
exclusive licence, the licensees agree to pay to SCYNEXIS an upfront payment of US$10
million plus potential milestone payments and royalties.
The product is a first-in-class, novel triterpenoid antifungal agent with broad-spectrum
activity providing the therapeutic advantages of both intravenous and oral formulations.
(RC)

Back to Others

Remark: Real time quote last updated: 17/09/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.